Answers are grounded in this paper and cite their sources.
Population-based case-control study finds no link between CSF1 genetic variability and Alzheimer's disease risk.
BACKGROUND: Colony-stimulating factor 1 (CSF1) regulates the proliferation and differentiation of myelomonocytic cells. Microglial cells of CSF1-deficient mice are reduced in number and are functionally impaired. CSF1-deficient mice exhibit subtle neurodevelopmental defects, enhanced neuronal vulnerability. Moreover, it has been reported that these mice may have amyloid-plaque-like depositions in the brain at an early age. The human CSF1 gene maps to chromosome 1p21-p13, a region previously linked to Alzheimer's disease (AD). Thus, CSF1 is a functional and positional candidate gene for AD. OBJECTIVE: We assessed if genetic variability of CSF1 may influence the risk for AD. METHODS: We conducted a population-based case-control association study with 3 single nucleotide polymorphisms (SNPs) across the CSF1 locus in a sample of n = 185 (rs3093054, rs756325) and n = 327 (rs1058885) individuals. RESULTS: None of the 3 investigated SNPs was associated with the risk for AD in our sample. CONCLUSION: These data do not support the hypothesis that genetic variability of CSF1 influences the risk for AD.
No takes yet. Share an insight, caveat, or question.
Wollmer et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: